TY - JOUR
T1 - Progress report on new antiepileptic drugs
T2 - A summary of the Seventh Eilat Conference (EILAT VII)
AU - Bialer, Meir
AU - Johannessen, Svein I.
AU - Kupferberg, Harvey J.
AU - Levy, René H.
AU - Perucca, Emilio
AU - Tomson, Torbjörn
PY - 2004/9
Y1 - 2004/9
N2 - The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the 9th to 13th May 2004. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included advances in pathophysiology of drug resistance, new AEDs in pediatric epilepsy syndromes, modes of AED action and spectrum of adverse effects and a re-appraisal of comparative responses to AED combinations. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on second-generation AEDs. This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel, ucb 34714 and valrocemide (TV 1901). Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, new oral and parenteral formulations of valproic acid and SPM 927 and the antiepileptic vagal stimulator device are also presented.
AB - The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the 9th to 13th May 2004. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included advances in pathophysiology of drug resistance, new AEDs in pediatric epilepsy syndromes, modes of AED action and spectrum of adverse effects and a re-appraisal of comparative responses to AED combinations. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on second-generation AEDs. This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel, ucb 34714 and valrocemide (TV 1901). Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, new oral and parenteral formulations of valproic acid and SPM 927 and the antiepileptic vagal stimulator device are also presented.
KW - Antiepileptic drugs
KW - Clinical trials
KW - Conference
KW - Drug development
KW - Epilepsy
KW - Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=4644301804&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2004.07.010
DO - 10.1016/j.eplepsyres.2004.07.010
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15570674
AN - SCOPUS:4644301804
SN - 0920-1211
VL - 61
SP - 1
EP - 48
JO - Epilepsy Research
JF - Epilepsy Research
IS - 1-3
ER -